In recent years, China has produced over 300000 babies annually through assisted reproductive technology. In order to benefit more infertility patients with assisted reproductive technology projects, since last year, Beijing, Guangxi, Inner Mongolia, Gansu and other places have included this project in basic medical insurance, bringing happiness to many families. "On February 22nd, I graduated from the Department of Reproductive Medicine!" Looking at "Pregnancy Notes," 30-year-old Ms. Lu told reporters that after more than half a year of treatment, she finally became a expectant mother on this day. Ms. Lu comes from Nanning City, Guangxi Zhuang Autonomous Region. Due to infertility, she has been to more than 20 hospitals since June last year. Last September, she made her first attempt to receive assisted reproductive therapy at a cost of 32000 yuan, but it ended in failure. "At that time, there was a lot of pressure, and if it was necessary to 'implant' three or four times, it was indeed difficult to bear economically." "The cost of assisted reproductive transplantation cycle treatment was 30000 to 40000 yuan, and more than half of women needed to receive assisted reproductive treatment again or even multiple times, which was a heavy economic burden." said Yang Yihua, Deputy Director of the Guangxi Reproductive Medicine Research Center at the First Affiliated Hospital of Guangxi Medical University. In November 2023, the Medical Insurance Bureau of Guangxi Zhuang Autonomous Region, the Department of Human Resources and Social Security, and the Health Commission jointly issued a document to include some therapeutic assisted reproductive medical service projects in the payment scope of basic medical insurance and work-related injury insurance funds, without setting a minimum payment standard. The reimbursement rates for employee basic medical insurance and urban and rural resident basic medical insurance are 70% and 50%, respectively, and are included in the maximum annual fund payment limit of insured persons. This policy has effectively reduced the burden on infertile patients. Beijing is the earliest region in China to include assisted reproductive programs in basic medical insurance. "After the implementation of the three child policy, we launched a feasibility study on the inclusion of assisted reproductive technology projects in medical insurance." Han Bo, head of the Medical Service Department of the Beijing Medical Insurance Bureau, told reporters that in 2022, the Beijing Medical Insurance Bureau uniformly priced assisted reproductive technology projects such as in vitro fertilization and embryo cultivation. On the day of the announcement of the price policy, we dispatched staff to 15 hospitals that can implement assisted reproductive technology projects to explain the relevant price policies to patients. However, further calculation and verification are needed to determine whether they can be included in medical insurance. On July 1, 2023, Beijing officially included 16 therapeutic assisted reproductive technology projects in the reimbursement scope of basic medical insurance. "The highest cost of assisted reproduction is anesthesia for egg retrieval, embryo culture, and transplantation surgery, which happens to be included in the coverage of Beijing medical insurance, accounting for about 55% of the total cost." Li Rong, Vice Dean and Director of Reproductive Medicine at Peking University Third Hospital, told reporters that some patients need to undergo genetic diagnosis before embryo implantation, which is also within the scope of medical insurance reimbursement. Policy efforts have led to a decrease in costs related to assisted reproductive programs. In June 2023, the National Medical Insurance Administration issued the "Guidelines for the Approval of Price Items for Assisted Reproductive Medical Services (Trial)", which classified and integrated the originally diverse assisted reproductive services in various regions into 12 items. As of now, 20 provinces have changed their pricing methods from market adjusted prices to government guided prices, further standardizing the prices of assisted reproductive medical services,